Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 1,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock in a transaction that occurred on Monday, July 27th. The shares were bought at an average price of $13.62 per share, for a total transaction of $20,430.00. Following the transaction, the chief executive officer owned 5,609,202 shares in the company, valued at $76,397,331.24. This represents a 0.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Thursday, July 23rd, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $13.14 per share, for a total transaction of $32,850.00.
• On Friday, July 24th, Snehal Patel acquired 1,100 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $12.88 per share, with a total value of $14,168.00.

Greenwich LifeSciences Trading Down 5.1%

Shares of NASDAQ GLSI opened at $12.77 on Thursday. Greenwich LifeSciences, Inc. has a 1-year low of $7.78 and a 1-year high of $34.10. The company has a market cap of $187.46 million, a PE ratio of -8.13 and a beta of 1.40. The company has a 50-day moving average of $21.34 and a two-hundred day moving average of $24.20.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GLSI. Bank of America Corp DE grew its position in shares of Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the period. Rhumbline Advisers raised its stake in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Greenwich LifeSciences by 109.6% in the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after buying an additional 4,102 shares during the period. Strs Ohio acquired a new position in Greenwich LifeSciences in the first quarter valued at approximately $177,000. Finally, Jane Street Group LLC bought a new position in Greenwich LifeSciences in the fourth quarter valued at approximately $203,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wall Street Zen cut shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Finally, HC Wainwright lifted their target price on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $57.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.